Last reviewed · How we verify

Preservative Free Morphine

Icahn School of Medicine at Mount Sinai · FDA-approved active Small molecule

Preservative Free Morphine is a Opioid agonist Small molecule drug developed by Icahn School of Medicine at Mount Sinai. It is currently FDA-approved for Moderate to severe acute and chronic pain, Palliative care and cancer pain. Also known as: Duramorph.

Morphine is an opioid agonist that binds to mu opioid receptors in the central and peripheral nervous system to produce analgesia and other opioid effects.

Morphine is an opioid agonist that binds to mu opioid receptors in the central and peripheral nervous system to produce analgesia and other opioid effects. Used for Moderate to severe acute and chronic pain, Palliative care and cancer pain.

At a glance

Generic namePreservative Free Morphine
Also known asDuramorph
SponsorIcahn School of Medicine at Mount Sinai
Drug classOpioid agonist
TargetMu (μ) opioid receptor
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Morphine activates mu (μ) opioid receptors, which are G-protein coupled receptors found throughout the brain, spinal cord, and peripheral tissues. This activation modulates pain perception, reduces anxiety, and produces sedation. The preservative-free formulation eliminates additives that may cause adverse reactions, making it suitable for sensitive patient populations or specific routes of administration such as intrathecal or epidural delivery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Preservative Free Morphine

What is Preservative Free Morphine?

Preservative Free Morphine is a Opioid agonist drug developed by Icahn School of Medicine at Mount Sinai, indicated for Moderate to severe acute and chronic pain, Palliative care and cancer pain.

How does Preservative Free Morphine work?

Morphine is an opioid agonist that binds to mu opioid receptors in the central and peripheral nervous system to produce analgesia and other opioid effects.

What is Preservative Free Morphine used for?

Preservative Free Morphine is indicated for Moderate to severe acute and chronic pain, Palliative care and cancer pain.

Who makes Preservative Free Morphine?

Preservative Free Morphine is developed and marketed by Icahn School of Medicine at Mount Sinai (see full Icahn School of Medicine at Mount Sinai pipeline at /company/icahn-school-of-medicine-at-mount-sinai).

Is Preservative Free Morphine also known as anything else?

Preservative Free Morphine is also known as Duramorph.

What drug class is Preservative Free Morphine in?

Preservative Free Morphine belongs to the Opioid agonist class. See all Opioid agonist drugs at /class/opioid-agonist.

What development phase is Preservative Free Morphine in?

Preservative Free Morphine is FDA-approved (marketed).

What are the side effects of Preservative Free Morphine?

Common side effects of Preservative Free Morphine include Constipation, Nausea, Drowsiness, Dizziness, Respiratory depression, Dependence and tolerance.

What does Preservative Free Morphine target?

Preservative Free Morphine targets Mu (μ) opioid receptor and is a Opioid agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing